System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Pierre Vera is an expert in Nuclear medicine at Centre Henri Becquerel (France). As of July 2026, ScienceLeadR ranks Pierre Vera in the top 1% of experts worldwide for Lung Neoplasms and Thoracic Neoplasms. Pierre Vera has authored 477 publications, the most recent in 2026, and is an investigator in 17 clinical trials, 1 of them ongoing. SLR score: 1,423 (community average: 125). How the SLR is computed.

LeadR Profile

Pierre Vera Centre Henri Becquerel France
1 423 ScienceLeadR Reputation 1423

Unlock

Register Login
Network Map

Nuclear medicine

Subspecialties: Oncology - Neurology - Medical Imaging

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1997 - 2026
Source: PubMed

Hôpital Charles-Nicolle (France)

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 477

Citations

Citations: 9 494 1st author: 38 Last author: 136 Unique author: 3

Main journals

HAL (Le Centre pour la Communication Scientifique Directe) 78
MED NUCL 58
Eur J Nucl Med Mol Imaging 22
Cancer Radiother 21
J Nucl Med 18

Best Journals

Lancet Oncol 2
N Engl J Med 2
Ann Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Automatic lesion segmentation in ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT: added value of PET-guided SPECT in a bicentric study.
PMID 42387196 — single photon emission computed tomography computed tomography, neoplasms, prostate, positron emission tomography computed tomography, neoplasm metastasis, tomography, emission-computed, single-photon, prostatic neoplasms, therapeutics		EJNMMI Res20260
Predicting survival of patients treated with antibody-drug conjugates in early-phase clinical trials using AI-quantified 3D body composition on CT scans.
PMID 42211497 — safety, pharmaceutical preparations, body composition, multivariate analysis, therapeutics, artificial intelligence, tissues, adipose tissue		Front Oncol20260
GMP-compliant automated synthesis and quality control of [ 177Lu]Lu-PSMA-I&T using the GAIA/LUNA Elysia-Raytest module for the treatment of metastatic castration-resistant prostate cancer.
PMID 42154134 — quality control, neoplasms, prostate, prostatic neoplasms, castration, therapeutics		EJNMMI Radiopharm Chem20260
Clinical value of per-treatment whole-body single-time-point automated dosimetry for [ 177Lu]Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer.
PMID 41792565 — blood, single photon emission computed tomography computed tomography, neoplasms, prostate, prostatic neoplasms, castration, therapeutics		Eur J Nucl Med Mol Imaging20260
From Nuclear Medicine Specialist to Cancer Center Director: Jeremie Calais Talks with Pierre Vera about Leading Through Change in Nuclear Medicine.
PMID 40935612 — neoplasms, nuclear medicine		J Nucl Med20250

Clinical Studies 17

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

Phase 2 7
N/A 6
Phase 3 4

By status:

Completed 11
Unknown 3
Active not recruiting 2
Recruiting 1

By type:

Interventional 15
Observational 2

By Monocentric/Multicentric:

monocentric 12
multicentric2to4 1
multicentric5to9 1
multicentricup10 3

Main Topics

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Telephone Support vs Self guidance in an Internet based Self administered Psychological Program to Address Depression
NCT06230237 — depression, telephone, internet, smiling, depressive disorder, internet-based intervention, therapeutics, psychosocial intervention, mental health, emotional regulation		N/ARecruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS